ArticleCureus2025
Reversible Cerebral Vasoconstriction Syndrome Secondary to Paroxetine and Opioid Use in a Middle-Aged Woman: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reversible Cerebral Vasoconstriction Syndrome Associated With Vortioxetine: A Case Report.Cureus · 2026Article
- Post-stroke headache: a review of epidemiology, pathophysiology, and clinical management.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reversible cerebral vasoconstriction syndrome (RCVS) is a condition that usually presents with recurrent thunderclap headaches, focal neurological deficits, and seizures, secondary to transient cerebral vascular spasms. Although the mechanism is not well understood, medications that modulate serotonergic activity, such as selective serotonin reuptake inhibitors (SSRIs), may induce RCVS. In this case, we present a 39-year-old female patient with thunderclap headaches and a multitude of neurological deficits, including vision loss and musculoskeletal weakness. Her medical history is significant for depression, migraines, and opioid-use disorder in remission, treated with paroxetine and mirtazapine, sumatriptan, and buprenorphine-naloxone, respectively. The diagnosis of RCVS was supported by imaging that demonstrated multiple acute cerebral infarcts and stenoses. The patient spent a total of eight days as an inpatient, and during that time, her symptoms showed gradual improvement. RCVS is a rare condition that should be considered in a patient with risk factors for whom high-acuity diagnoses such as subarachnoid hemorrhage have been ruled out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.